نتایج جستجو برای: taxane

تعداد نتایج: 2009  

2015
S. Gandhi O. C. Freedman

chemotherapy is not recommended for the adjuvant treatment of breast cancer in any patient population. Anthracycline–taxane-based polychemotherapy regimens are, overall, considered superior to earliergeneration regimens and have the most significant impact on patient survival outcomes. Regimens with varying anthracycline and taxane doses and schedules are options; in general, paclitaxel given e...

Journal: :Archives of otolaryngology--head & neck surgery 2008
George H Yoo Geetha Subramanian Marie P Piechocki John F Ensley Omer Kucuk Ozlem E Tulunay Fulvio Lonardo Harold Kim Joshua Won Timothy Stevens Ho-Sheng Lin

OBJECTIVES To identify the antitumor activity and wound-healing effect of docetaxel delivered in the surgical tumor microenvironment of head and neck squamous cell carcinoma (HNSCC). DESIGN Control and experimental series. SETTING Academic medical center. SUBJECTS BALB/c and severe combined immunodeficiency mice. INTERVENTION Intrawound (IW) docetaxel therapy was tested in 3 HNSCC xenog...

ژورنال: کومش 2010
حاجی‌زاده, ابراهیم, خدابخشی, رضا, فردمال, جواد, کاظم‌نژاد, انوشیروان, گوهری, محمودرضا,

سابقه و هدف: شیمی ‌درمانی از اجزای درمان‌های تکمیلی پس از جراحی مبتلایان به سرطان پستان است. هدف این مطالعه، مقایسه کارایی رژیم‌های درمان تکمیلی Taxane-based و Anthracycline-based با Cyclophosphamide, Methotrexate و5-fluorouracil (CMF) بعد از جراحی ماستکتومی تعدیل شده(Modified radical mastectomy ,MRM) از نظر مدت زمان فراغت از بیماری بود. مواد و روش‌ها: 62 بیمار مبتلا به سرطان پستان که تحت ...

2011
Abraham Mendoza Yoshihiro Ishihara Phil S. Baran

Taxanes form a large family of terpenes comprising over 350 members, the most famous of which is Taxol (paclitaxel), a billion-dollar anticancer drug. Here, we describe the first practical and scalable synthetic entry to these natural products via a concise preparation of (+)-taxa-4(5),11(12)-dien-2-one, which has a suitable functional handle with which to access more oxidized members of its fa...

2010
Maria T. Baquero

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing...

2016
Gyöngyvér Szentmártoni Anna-Mária Tőkés Timea Tőkés Krisztián Somlai Attila Marcell Szász László Torgyík Janina Kulka Magdolna Dank

AIM To identify breast cancer subtypes likely to respond to primary systemic therapy (PST or neoadjuvant therapy) and to assess the accuracy of physical examination (PE) and breast ultrasonography (US) in evaluating and predicting residual size of breast carcinoma following PST. METHODS 116 patients who received at least two cycles of PST between 1998 and 2009 were selected from a prospective...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
I E Smith J-Y Pierga L Biganzoli H Cortés-Funes C Thomssen X Pivot A Fabi B Xu D Stroyakovskiy F A Franke B Kaufman P Mainwaring T Pienkowski B De Valk A Kwong J L González-Trujillo I Koza K Petrakova D Pereira K I Pritchard

BACKGROUND First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label study further assesses first-line bevacizumab with taxane-based chemotherapy in routine oncology practice. PATIENTS AND METHODS Patients ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2015
M Nakazawa C Lu Y Chen C J Paller M A Carducci M A Eisenberger J Luo E S Antonarakis

BACKGROUND We previously showed that pretreatment detection of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer is associated with resistance to abiraterone and enzalutamide, but not to taxane chemotherapies. Here, we conducted serial measurements of AR-V7 and evaluated patterns of longitudinal AR-V7 dynamics over th...

Journal: :Expert Opinion on Therapeutic Patents 2015

Journal: : 2023

Mục tiêu: Đánh giá thời gian sống thêm bệnh không tiến triển (PFS) của nhân ung thư vú HER2-dương tính tái phát, di căn hóa trị bước 1 phác đồ docetaxel kết hợp trastuzumab. Đối tượng và phương pháp: Nghiên cứu mô tả hồi trên 56 giai đoạn được trastuzumab từ tháng 01/2015 tới 10/2022 tại Bệnh viện K. Kết quả: Tuổi trung bình ở điểm là 53,1±14,3 tuổi. Trung vị PFS nhóm nghiên 13,0 tháng. Tỷ lệ 6...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید